Patents by Inventor Wayne TSUJI

Wayne TSUJI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteins specific for BAFF and B7RP1 and uses thereof
    Patent number: 11492417
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: November 8, 2022
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
  • Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
    Publication number: 20220135668
    Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Inventors: John P. Gibbs, II, Wayne Tsuji, Wei-Jian Pan
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
    Publication number: 20210206881
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: September 23, 2019
    Publication date: July 8, 2021
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
  • METHODS FOR TREATING CHRON'S DISEASE USING AN ANTI-IL23 ANTIBODY
    Publication number: 20200283517
    Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.
    Type: Application
    Filed: May 8, 2020
    Publication date: September 10, 2020
    Inventors: Wei-Jian Pan, Wayne Tsuji
  • Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
    Publication number: 20200277368
    Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.
    Type: Application
    Filed: October 10, 2019
    Publication date: September 3, 2020
    Inventors: John P. Gibbs, II, Wayne Tsuji, Wei-Jian Pan
  • METHODS FOR TREATING CHRON'S DISEASE USING AN ANTI-IL23 ANTIBODY
    Publication number: 20200017581
    Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 16, 2020
    Inventors: Wei-Jian Pan, Wayne Tsuji
  • Proteins specific for BAFF and B7RP1
    Patent number: 10421824
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
  • Proteins specific for BAFF and B7RP1 and uses thereof
    Patent number: 10421823
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
  • METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY
    Publication number: 20180327490
    Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.
    Type: Application
    Filed: November 21, 2017
    Publication date: November 15, 2018
    Inventors: Wei-Jian Pan, Wayne Tsuji
  • METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY
    Publication number: 20170218062
    Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinctics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Wei-Jian Pan, Wayne Tsuji
  • Proteins Specific for BAFF and B7RP1
    Publication number: 20170066845
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 9, 2017
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
  • Proteins specific for BAFF and B7RP1
    Patent number: 9458246
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 4, 2016
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
  • METHODS FOR TREATING PSORIASIS USING AN ANTI-IL-23 ANTIBODY
    Publication number: 20160060337
    Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.
    Type: Application
    Filed: February 25, 2014
    Publication date: March 3, 2016
    Inventors: John P. Gibbs, Wayne Tsuji, Wei-Jian Pan
  • METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY
    Publication number: 20160031983
    Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.
    Type: Application
    Filed: February 25, 2014
    Publication date: February 4, 2016
    Inventors: Wei-Jian Pan, Wayne Tsuji
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
    Publication number: 20160024225
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1
    Publication number: 20140302036
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 9, 2014
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne TSUJI